Generic drugmaker Teva makes $40 billion offer for rival Mylan

TEL AVIV/NEW YORK (Reuters) – Teva Pharmaceutical Industries Ltd. on Tuesday made an unsolicited $40 billion offer for smaller rival Mylan NV, a bold bid for growth as its lucrative Copaxone drug faces generic competition.




Source: Business

Leave a Reply

Your email address will not be published. Required fields are marked *

18 − fifteen =